Tenon Medical Q4 revenue, gross profit surge
Overview
US medical device maker's Q4 2025 revenue rose 92% yr/yr to $1.5 mln
Gross profit for Q4 2025 increased 188% yr/yr, with gross margin rising to 69%
Outlook
Company did not provide specific guidance for future quarters or the full year in press release
Result Drivers
PROCEDURE GROWTH - Co said FY revenue increase was primarily due to more surgical procedures in the second half of 2025 across Catamaran and SImmetry+ platforms, driven by adoption from new physician users
GROSS MARGIN IMPROVEMENT - Co said higher revenue in second half of 2025 led to better absorption of fixed costs, improving gross margin
Company press release: ID:nACS48z54a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $1.5 mln | $1.38 mln (2 Analysts) |
Q4 Net Income |
| -$2.8 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Tenon Medical Inc is $2.75, about 231.3% above its March 18 closing price of $0.83
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
